Communicating the Results of Clinical Research to Participants: Attitudes, Practices, and Future Directions

Shalowitz, David I.; Miller, Franklin G.
May 2008
PLoS Medicine;May2008, Vol. 5 Issue 5, pe91
Academic Journal
The authors discuss the available data on the effects of communicating aggregate and individual research results on participants, investigators, and the research enterprise.


Related Articles

  • Optimizing clinical trials recruitment via deep learning. Gligorijevic, Jelena; Gligorijevic, Djordje; Pavlovski, Martin; Milkovits, Elizabeth; Glass, Lucas; Grier, Kevin; Vankireddy, Praveen; Obradovic, Zoran // Journal of the American Medical Informatics Association;Nov2019, Vol. 26 Issue 11, p1195 

    Objective: Clinical trials, prospective research studies on human participants carried out by a distributed team of clinical investigators, play a crucial role in the development of new treatments in health care. This is a complex and expensive process where investigators aim to...

  • An audit of clinical trials registered at clinical trial registry of India in 2017. Panchasara, Ashwin K.; Chawda, Hiren M. // National Journal of Physiology, Pharmacy & Pharmacology;2018, Vol. 8 Issue 9, p1293 

    No abstract available.

  • TRADE SECRETS.  // Applied Clinical Trials;Nov2000, Vol. 9 Issue 11, p86 

    Gives advice to clinical research professionals concerning key business concepts that apply to clinical research. Importance of recognizing the assets of clinical research organizations; Business intelligence; Standard business practices; Use of benchmarking in identifying areas for...

  • Serious adverse events in academic critical care research. Cook, Deborah; Lauzier, Fran├žois; Rocha, Marcelo G.; Sayles, Mary Jane; Finfer, Simon // CMAJ: Canadian Medical Association Journal;4/22/2008, Vol. 178 Issue 9, p1181 

    The article discusses proposed solutions for more rational reporting of serious adverse events in academic critical care trials of drugs in common use. According to the authors, investigators must clearly describe the serious adverse events that they plan to identify and report in their protocol...

  • Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. Hanley, Bec; Truesdale, Ann; King, Andy; Elbourne, Diana; Chalmers, Iain // BMJ: British Medical Journal (International Edition);03/03/2001, Vol. 322 Issue 7285, p519 

    Conclusions: Consumer involvement in the design and conduct of controlled trials seems to be growing and seems to be welcomed by most researchers. Such involvement seems likely to improve the relevance to consumers of the questions addressed and the results obtained in controlled trials.

  • Statistics Notes: Concealing treatment allocation in randomised trials. Altman, Douglas G; Schulz, Kenneth F // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p446 

    Discusses the importance of concealing treatment allocation until a patient has entered a randomised clinical trial. Attempts to eliminate bias; How to ensure that allocation sequence will be concealed, including using external help; Difference between randomised and double blind trials.

  • Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. Evans; Pocock; Lievre, Michel; Menard, Joel; Bruckert, Eric; Cogneau, Joel; Delahaye, Francois; Giral, Philippe; Leitersdorf, Eran; Luc, Gerald; Masana, Luis; Moulin, Philippe; Passa, Philippe; Pouchain, Denis; Siest, Gerard // BMJ: British Medical Journal (International Edition);03/10/2001, Vol. 322 Issue 7286, p603 

    Discusses premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. Reasons why some trials are discontinued prematurely by their sponsor for strategic reasons; How public financial and scientific participation in some trials and increasing the...

  • Monitoring and Ensuring Safety During Clinical Research. Morse, Michael A.; Califf, Robert M.; Sugarman, Jeremy // JAMA: Journal of the American Medical Association;3/7/2001, Vol. 285 Issue 9, p1201 

    Addresses concerns regarding the protection of human subjects in clinical trials. Description of the manner in which adverse event reporting might function to enhance safety; Role of data monitoring committees in using aggregate data from these reports; Problems that exist for institutional...

  • Intention-to-treat analysis: Protecting the integrity of randomization. Mahaniah, Kiame J.; Rao, Goutham // Journal of Family Practice;Aug2004, Vol. 53 Issue 8, p644 

    Randomization is a crucial part of most clinical trials. The purpose of randomization in a trial comparing 2 groups is to ensure that the groups differ only with respect to the interventions being compared. Randomization determines not only which treatment subjects receive, but also how the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics